Bertilimumab: Preliminary Ph II data

Preliminary data from 3 patients with moderate to extensive bullous pemphigoid in an open-label, U.S. and Israeli Phase II trial showed that 10 mg/kg IV bertilimumab on days 0, 14 and 28 led to a mean reduction in BPDAI score of 84%. Additionally, the patients' oral prednisone dose was tapered down to ≤10 mg/day. Based on the data, Immune Pharmaceuticals said it has broadened enrollment criteria in the trial from newly diagnosed patients to include bullous pemphigoid patients who are having difficulty being tapered off of chronic steroids. Bullous pemphigoid is a rare autoimmune blistering disease of the skin...